Eagle Pharmaceuticals (EGRX) Tops Q3 EPS by 12c

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q3 EPS of $0.77, $0.12 better than the analyst estimate of $0.65. Revenue for the quarter came in at $37.8 million versus the consensus estimate of $41.04 million.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.

You May Also Be Interested In

• Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
• Occidental Petroleum releases Q2 2026 earnings considerations
• Benchmark Reiterates Buy Rating on Penske Automotive Group (PAG)